PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDasiglucagon
Dasiglucagon
Zegalogue (dasiglucagon) is an unknown pharmaceutical. Dasiglucagon was first approved as Zegalogue on 2021-03-22. It is used to treat hypoglycemia in the USA.
Download report
Favorite
FDA Novel Drug Approvals 2021
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Zegalogue
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dasiglucagon hydrochloride
Tradename
Company
Number
Date
Products
ZEGALOGUEZealand PharmaN-214231 RX2021-03-22
1 products, RLD, RS
ZEGALOGUE (AUTOINJECTOR)Zealand PharmaN-214231 RX2021-03-22
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
zegalogueNew Drug Application2024-12-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypoglycemia—D007003E16.2
Agency Specific
FDA
EMA
Expiration
Code
DASIGLUCAGON HYDROCHLORIDE, ZEGALOGUE, ZEALAND PHARMA
2026-03-22NCE
DASIGLUCAGON HYDROCHLORIDE, ZEGALOGUE (AUTOINJECTOR), ZEALAND PHARMA
2026-03-22NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Dasiglucagon Hydrochloride, Zegalogue, Zealand Pharma
104428472035-02-03DS, DP
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoglycemiaD007003—E16.2466——16
Type 1 diabetes mellitusD003922EFO_0001359E10266——13
Diabetes mellitusD003920EFO_0000400E08-E13234——9
Congenital hyperinsulinismD044903———33——5
NesidioblastosisD046768EFO_0007318E16.9—33——5
HyperinsulinismD006946—E16.1—13——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Glucose metabolism disordersD044882———1———1
Metabolic diseasesD008659EFO_0000589E88.9—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDasiglucagon
INNdasiglucagon
Description
Dasiglucagon, sold under the brand name Zegalogue, is a medication used to treat severe hypoglycemia in people with diabetes.
Classification
Small molecule
Drug classsynthetic glucagon analogs
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1544300-84-6
RxCUI—
ChEMBL IDCHEMBL4297741
ChEBI ID—
PubChem CID126961379
DrugBankDB15226
UNII IDAD4J2O47FQ (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 137 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
18 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use